MGTX
MeiraGTx Holdings plc
NASDAQ · Healthcare · Biotechnology · US
$13.76
−1.54%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
5.0x
Market Cap
$1.32B
MomentumView details →
1D Return
−1.54%
YTD Return
+72.83%
RSI (14)
51.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
5.0x
Market Cap
$1.32B
RSI (14)
51.6
MomentumView details →
1D Return
−1.54%
YTD Return
+72.83%
SummaryUpdated Jun 1, 2026
MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage gene therapy company founded in 2015 and based in New York. The company went public in June 2018 and focuses on developing innovative gene therapies to treat patients with serious diseases, particularly inherited blindness and other ocular conditions, as well as neurodegenerative diseases. MeiraGTx operates at the cutting edge of biotechnology, using advanced genetic engineering techniques to potentially cure diseases that currently have limited or no treatment options.
Similar companies
Latest newsMore news →
MeiraGTx Holdings PLC reported Q2 2026 earnings of $1.71 per share, surpassing the Zacks Consensus Estimate of a loss of $0.39 per share, and compared to a loss of $0.48 per share a year ago.22d agoMeiraGTx raised $100 million in equity financing concurrent with the bota-vec acquisition.22d agoMeiraGTx completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for $25 million.22d ago